Kyle is an early-stage investor andactive contributor to Canada's life sciences and deep tech ecosystem, with afocus on translating university and lab-born science into commercial ventures.

Before joining Celesta, Kyle worked atthe intersection of research and commercialization within McMaster University'shealth-innovation community, including hands-on venture-building through TheClinic, where he helped advance early-stage medical technology from prototypetoward company formation. His work spans biotech, medtech, and the growingconvergence of AI with drug discovery and health.

Kyle holds a PhD in bioengineering fromMcMaster University, where his research spanned phage therapy, biotechnology,and biomedical innovation — grounding his investment work in a deepunderstanding of the science behind the companies he backs.

‍